1,721,138 research outputs found
Red blood cell alloimmunization in sickle cell disease and in thalassaemia: Current status, future perspectives and potential role of molecular typing
No full textRed blood cell (RBC) transfusions are a milestone in the treatment for sickle cell anaemia (SSA) and for thalassaemia. RBC alloimmunization remains a major challenge of chronic transfusion therapy, and it can lead to adverse life-threatening events. The alloimmunization risk could depend on multiple factors such as the number of transfusions and, most of all, the genetic background. Different ethnic groups are predisposed to immunization because of a significant degree of RBC antigenic mismatch between donor and recipient. There is no universal agreement and standards for the most appropriate selection of RBC units in chronically transfused subjects. Current practice only deals with compatibility of ABO, Rh and K antigens. Molecular RBC antigenic matching extended to other blood group systems is an innovative strategy to ensure a better quality and effectiveness of transfusion therapy. © 2013 International Society of Blood Transfusion
Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Gruppo Italiano di Studio per la Manipolazione Cellulare in Ematologia.
No full textRecovery phase infection patterns in 55 patients who had undergone autologous blood progenitor cell transplantation (ABPCT) were evaluated retrospectively. The results were compared to those obtained in a group of 41 patients who received autologous bone marrow transplantation (ABMT). Fever related to documented or suspected infection developed in 38 of 55 patients in the ABPCT group and in 37 of 41 in the ABMT group (p 0.05). However, fewer acquired systemic fungal infections (1/55 vs. 5/41, p < 0.05) as well as fewer days of antibiotic usage were observed in the ABPCT group
The application of multiparameter reference intervals for pre-donation capillary blood counts: the experience of a single institution
No full textObjectives: To evaluate a set of reference counts applied to multiparameter pre-counts in blood donors. Aim: Analyse the impact of pre-donation counts and specific reference intervals on donors' management. Background: Multiparameter blood counts allow an improved enrolment process of blood donors due to a prompt identification of abnormalities involving haemoglobin (Hb), white blood cells (WBC) and platelets (PLT). Methods/Materials: Multiple pre-donation capillary counts were applied in the enrolment process of 13 347 consecutive donors. The rate of specific alterations of permanent exclusion and donor readmittance to donations for temporary exclusion had been evaluated, applying a set of multiparameter reference intervals. Results: Alterations involved Hb in 72.55% of cases, mean corpuscular volume (MCV) in 20.99%, total WBC in 9.39%, lymphocytes in 7.55% and PLT in 6.07%. Among donors with initial alterations (543; 4.06%), 12.70% were readmitted to donations within 15 days, 14.36% had permanent exclusion, 36.83% underwent prompt supplementation treatment and 36.09% were lost at follow-up or refused treatments. Discussion: The systematic use of blood count reference intervals and pre-donation multiparameter blood counts allowed prompt identification of WBC, PLT and MCV alterations, readmittance within 15 days of 12.70% of initially excluded donors and contributed to prompt management of supplement deficiency
Central venous catheter insertion in peripheral blood hematopoietic stem cell sibling donors: The SIdEM (Italian Society of Hemapheresis and Cell Manipulation) point of view
No full textCollection of peripheral blood hematopoietic stem cells (PBSC) is the practice of choice for graft procurement in both autologous and allogeneic setting. The success of this procedure depends on the use of adequate vascular accesses. Well-sized peripheral veins are the first option in autologous and allogeneic donations. In autologous setting, in case of lack of adequate veins, central venous catheters (CVC) may be used for collection. In the allogeneic setting, although available data have shown the safety of the use of CVC, there are still some controversies about the possible insertion of a CVC in donors. A specific policy from competent registries is usually applied in the different countries to regulate the use of CVC in unrelated donors. In siblings, the question is still undefined due both to the lack of shared guidelines and to the specific characteristics of this donation. In fact, in not so rare cases, larger stem cell doses for specific cell manipulations (e.g., T/B cell depletion in the haploidentical setting) are needed. The lack of international rules or standard that forbid the use of a CVC in siblings and published data that document the safety of this procedure, allowed the Societa Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) national Board to identify a possible, shared, operational approach to address this issue by a case-specific risk-benefit assessment. (C) 2014 Elsevier Ltd. All rights reserved
Preparing platelet lysate essentially free of contaminating agents used as coadjuvant for isolating e.g. stem cells, by exposing fraction to photochemical agent and UV rays, subjecting fraction to freezing, and centrifuging fraction
No full textPreparing platelet lysate essentially free of contaminating agents used as coadjuvant for isolating e.g. stem cells, by exposing fraction to photochemical agent and UV rays, subjecting fraction to freezing, and centrifuging fractio
Platelet lysate, uses and method for the preparation thereof/Lysat de plaquettes, ses utilisations et son procédé de préparation
No full textThe present invention relates to a rapid, simple, effective and economical method for preparing platelet lysate free of contaminants that can generate the transmission of diseases caused by viral, microbial, fungal or parasitic agents, also called inactivated lysate. The present invention relates to the use of the platelet lysate obtained as a coadjuvant for the culture, growth and/or expansion of stem cells, in particular mesenchymal, of mesenchymal stem cells derived from adipose tissue, fibroblasts and dendritic cells
The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of hematopoietic recovery with clinical benefit after peripheral blood progenitor cell tranplantation
No full text- …
